Zhejiang Xinguang Pharmaceutical Co., Ltd. (SHE:300519)
China
· Delayed Price · Currency is CNY 16.32
-0.08 (-0.49%)
Mar 11, 2026, 3:04 PM CST
SHE:300519 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 256.95 | 267.54 | 270.28 | 351.37 | 320.77 | 282.96 | Upgrade
|
| Other Revenue | 0.12 | 0.12 | 0.11 | 0.12 | 0.11 | 0.12 | Upgrade
|
| Revenue | 257.07 | 267.66 | 270.4 | 351.49 | 320.88 | 283.08 | Upgrade
|
| Revenue Growth (YoY) | -4.96% | -1.01% | -23.07% | 9.54% | 13.35% | -2.81% | Upgrade
|
| Cost of Revenue | 162.7 | 177.89 | 160.03 | 169.81 | 145.29 | 128.68 | Upgrade
|
| Gross Profit | 94.37 | 89.77 | 110.37 | 181.68 | 175.58 | 154.4 | Upgrade
|
| Selling, General & Admin | 40.33 | 41.5 | 43.64 | 50.61 | 49.27 | 46.59 | Upgrade
|
| Research & Development | 13.05 | 12.62 | 15.13 | 15.55 | 13.52 | 12.01 | Upgrade
|
| Other Operating Expenses | 3.76 | 3.5 | 3.43 | 4.26 | 4.22 | 4.07 | Upgrade
|
| Operating Expenses | 56.89 | 57.74 | 61.51 | 70.86 | 66.85 | 62.71 | Upgrade
|
| Operating Income | 37.48 | 32.03 | 48.87 | 110.82 | 108.73 | 91.69 | Upgrade
|
| Interest & Investment Income | 29.58 | 23.55 | 22.98 | 14.09 | 23.03 | 19.29 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.69 | -0.01 | -0.02 | -0.01 | -0.01 | 2.74 | Upgrade
|
| EBT Excluding Unusual Items | 67.75 | 55.57 | 71.83 | 124.9 | 131.74 | 113.72 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.02 | -0.07 | -0.29 | - | -0.71 | - | Upgrade
|
| Asset Writedown | 0.14 | -0.01 | 0.02 | 0 | -0.02 | -0.45 | Upgrade
|
| Other Unusual Items | 0.08 | 1.51 | 1.6 | 0.7 | 0.95 | 1.52 | Upgrade
|
| Pretax Income | 67.95 | 57.01 | 73.16 | 125.6 | 131.96 | 114.8 | Upgrade
|
| Income Tax Expense | 10.01 | 6.62 | 8.8 | 16.78 | 17.68 | 15.82 | Upgrade
|
| Net Income | 57.94 | 50.39 | 64.36 | 108.82 | 114.28 | 98.98 | Upgrade
|
| Net Income to Common | 57.94 | 50.39 | 64.36 | 108.82 | 114.28 | 98.98 | Upgrade
|
| Net Income Growth | 33.39% | -21.70% | -40.86% | -4.78% | 15.46% | 5.41% | Upgrade
|
| Shares Outstanding (Basic) | 166 | 163 | 161 | 160 | 161 | 160 | Upgrade
|
| Shares Outstanding (Diluted) | 166 | 163 | 161 | 160 | 161 | 160 | Upgrade
|
| Shares Change (YoY) | 3.71% | 1.03% | 0.54% | -0.58% | 0.83% | 0.30% | Upgrade
|
| EPS (Basic) | 0.35 | 0.31 | 0.40 | 0.68 | 0.71 | 0.62 | Upgrade
|
| EPS (Diluted) | 0.35 | 0.31 | 0.40 | 0.68 | 0.71 | 0.62 | Upgrade
|
| EPS Growth | 28.62% | -22.50% | -41.18% | -4.23% | 14.52% | 5.08% | Upgrade
|
| Free Cash Flow | 64.58 | 48.23 | 37.3 | 109.78 | 127.64 | 102.34 | Upgrade
|
| Free Cash Flow Per Share | 0.39 | 0.30 | 0.23 | 0.69 | 0.79 | 0.64 | Upgrade
|
| Dividend Per Share | 0.300 | 0.300 | 0.400 | 0.500 | 0.600 | 0.600 | Upgrade
|
| Dividend Growth | -25.00% | -25.00% | -20.00% | -16.67% | - | 33.33% | Upgrade
|
| Gross Margin | 36.71% | 33.54% | 40.82% | 51.69% | 54.72% | 54.54% | Upgrade
|
| Operating Margin | 14.58% | 11.97% | 18.07% | 31.53% | 33.88% | 32.39% | Upgrade
|
| Profit Margin | 22.54% | 18.83% | 23.80% | 30.96% | 35.62% | 34.96% | Upgrade
|
| Free Cash Flow Margin | 25.12% | 18.02% | 13.80% | 31.23% | 39.78% | 36.15% | Upgrade
|
| EBITDA | 52.53 | 46.97 | 63.64 | 124.88 | 121.59 | 104.22 | Upgrade
|
| EBITDA Margin | 20.43% | 17.55% | 23.54% | 35.53% | 37.89% | 36.82% | Upgrade
|
| D&A For EBITDA | 15.05 | 14.93 | 14.77 | 14.05 | 12.86 | 12.53 | Upgrade
|
| EBIT | 37.48 | 32.03 | 48.87 | 110.82 | 108.73 | 91.69 | Upgrade
|
| EBIT Margin | 14.58% | 11.97% | 18.07% | 31.53% | 33.88% | 32.39% | Upgrade
|
| Effective Tax Rate | 14.73% | 11.61% | 12.03% | 13.36% | 13.40% | 13.78% | Upgrade
|
| Revenue as Reported | 257.07 | 267.66 | 270.4 | 351.49 | 320.88 | 283.08 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.